Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by bone marrow fibrosis, cytopenias, splenomegaly, and elevated proinflammatory cytokine levels. The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is the central pathway implicated in the pathogenesis of MF. 1, 2 One of the other pathways dysregulated in MF includes the phosphatidylinositol-3-kinase (PI3K)/Akt pathway. 3 Ruxolitinib, a first-in-class JAK1/2 inhibitor (JAKi), is approved in the US and EU for treatment of MF and polycythemia vera after an inadequate response or intolerance to hydroxyurea.
Buparlisib, an oral pan-PI3K inhibitor, showed favorable tolerability/efficacy profile in patients with solid tumors. 4 Targeting multiple signaling pathways might have a synergistic therapeutic effect on the underlying pathogenesis of MF. 5 For patients who do not respond to JAKi or those who lose their response, a rational combination of other targeted agents is a promising strategy. 6, 7 Preclinical data suggest that inhibition of the PI3K/mTOR pathway has beneficial effects in MF. [8] [9] [10] The study comprised dose-escalation and expansion phases. In the dose-escalation phase, successive cohorts of minimum 3 patients received increasing doses of ruxolitinib (5 mg bid to 40 mg bid) and buparlisib (40 mg qd to 100 mg qd) until the MTD/RP2D was reached. An additional 6 patients were enrolled to determine a dose level as the MTD/RP2D.
The primary objective was to establish the MTD/RP2D of the combination of ruxolitinib and buparlisib in each arm as assessed by the incidence rate of DLTs. The key secondary objective was to evaluate safety.
Further details of the eligibility criteria, methods, other secondary objectives, and the statistical analysis used for this study are provided in the Online Supplementary Material.
Sixty-three patients (46% with primary MF, 31.7% with post-polycythemia vera MF, and 22.2% with post-essential thrombocythemia MF) were enrolled in the study (JAKi naïve, n=33; prior JAKi, n=30).
The baseline characteristics and patient disposition are summarized in Table 1 . At baseline, prior JAKi patients had lower hemoglobin and platelet counts and a higher white blood cell count compared with In the overall population, 5 patients (JAKi naïve, n=3; prior JAKi, n=2) experienced DLTs during the first 28 days; thrombocytopenia (JAKi naïve, n=2; prior JAKi, n=1), anxiety (JAKi naïve, n=1; prior JAKi, n=0), and depression (JAKi naïve, n=0; prior JAKi, n=1). MTD/RP2D was established at ruxolitinib 15 mg bid/buparlisib 60 mg qd (dose level 2) for both arms. 11 The MTD/RP2D remained the same as confirmed by the results of the expansion cohort, based on the 56 patients in the dose-determining set (Table 2 ).
All patients included in the safety set (n=63) experienced Primary AEs leading to study drug discontinuation in the MTD population included thrombocytopenia (n=3), anxiety (n=2), and depression (n=2) in the JAKi-naïve arm and progression to acute myeloid leukemia (n=2) in the prior JAKi arm. Dose reduction/interruptions in the JAKi-naïve arm and prior JAKi arm were due to thrombocytopenia (n=10; n=8, respectively) and anemia (n=2 in both arms).
The frequency of infections, thrombocytopenia, and psychiatric disorders were similar or slightly higher in the prior JAKi arm compared with the JAKi-naïve arm (Table 3) . Seven on-treatment deaths occurred, which were not related to the study treatment (Online Supplementary Figure 2A and Online Supplementary Figure   2B ). Best response in spleen volume reduction in MTD patients is presented in Online Supplementary Figure 2C .
There was remarkable improvement in global health status/quality of life, which was more prominent in the JAKi-naïve arm than the prior JAKi arm at both C7D1 and C12D28. Improvement in the 7-day Myelofibrosis Symptom Assessment Form (MFSAF) from baseline to week 24 in both the arms is shown in Online Supplementary To the best of our knowledge, HARMONY is the first study presenting safety and efficacy data on ruxolitinib and buparlisib combination in patients with MF. MTD for the combination was determined to be 15 mg bid for ruxolitinib and 60 mg qd for buparlisib in both JAKi-naïve and prior JAKi arms.
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Individual MTDs were 25 mg bid for ruxolitinib and 100 mg qd for buparlisib. 12, 13 In our study, MTD for the combination constituted lower doses for both the drugs when compared with the single agents.
Additionally, no unexpected DLTs were observed with the combination. Thrombocytopenia, anxiety, and depression were the DLTs observed with the combination in our study, which are consistent with the known profile of these 2 drugs. 14, 15 In our study, the anticipated synergistic effect of the combination was not observed on spleen response. The combination demonstrated a modest effect in JAK allele burden in both the arms, and only a few patients had improvement or stabilization in bone marrow fibrosis. However, 2 factors have to be taken into account before interpreting this data; the small sample size and short duration of the study.
Based on the modest, overall benefit-risk profile and efficacy, the ruxolitinib and buparlisib combination will not be progressed at this time. 
HARMONY Letter to the Editor Supplemental Material Eligibility criteria
Patients were eligible to enroll in the study if they met all the following criteria at screening: Patients who have had splenic irradiation within 12 months prior to screening, patients with specific mood disorders, active infection, inadequate liver or renal function, history of bleeding diathesis, and patients who were ready for a stem cell transplantation at the time of the screening were excluded.
Methods
As per protocol, disease progression was defined as a spleen length increase of >40% from the baseline as assessed by palpation. The end of study had occurred after all patients in the study had completed their last assessment as per protocol. The dose escalation was guided by a Bayesian logistic regression model with overdose control, dependent on dose-limiting toxicities (DLTs) in cycle 1 and other safety findings. A DLT was defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first 28 days.
The MTD/RP2D was defined as the dose level most closely associated with a posterior DLT probability of between 16% and 35% that does not also have a greater than 25% of probability of excessive toxicity (determined independently for both the arms). Once the MTD level was reached, patients entered in the expansion phase. In the expansion phase, an additional 10 patients in each arm, in addition to those treated at the MTD and/or RP2D during dose escalation, were treated at the respective MTD and/or RP2D for their respective arm. In total, approximately 62 patients were planned to be enrolled in dose determining set. Unless specified otherwise, safety and efficacy data presented were by dose level, by arm, and for overall and/or MTD population.
Other secondary objectives
The 
Statistical analysis
No formal statistical power calculations were performed to determine the sample size of this study. The full analysis set included all patients who received at least one dose of ruxolitinib or buparlisib. The safety set included all patients who received at least one dose of ruxolitinib or buparlisib, and had at least one valid post-baseline safety assessment. The dose-determining set consisted of all patients from the safety set who either met a minimum exposure criterion (received ≥80% of twice daily doses of ruxolitinib and ≥80% of planned daily doses of buparlisib) and had sufficient safety evaluations during cycle 1 or experienced a DLT during cycle 1. The pharmacokinetic (PK) analysis set consisted of all patients who had at least one blood sample providing evaluable PK data. The study was not adequately powered to assess the specific biomarker-related hypotheses; thus, statistical analyses of these data should be considered to be exploratory in nature. Missing post-baseline assessments 9.1% (1) 9.1% (1) N is the number of patients in Full Analysis Set. Percentages above use N as denominator. Supplementary Table 2 In the above figure, the green color indicates improvement; the orange color indicates stabilization, and the red color indicates worsening of bone marrow fibrosis. EOT=end of treatment; JAKi=Janus kinase inhibitor.
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